Metraipolis › archive › dc_67387fe694f7
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41874648
- DOI
- 10.1007/s00262-[numero omesso]-9
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T05:17:11.040Z
- SHA-256 of the archived text
83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4- Stable URL of this page
https://metraipolis.com/documento/dc_67387fe694f7
How to cite
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648 — Europe PMC (en), https://europepmc.org/article/MED/41874648 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_67387fe694f7 (Metraipolis archive dc_67387fe694f7, sha256 83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4)
BibTeX
@misc{dc67387fe694f7,
title = {Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation… — Europe PMC PMID:41874648},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41874648},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_67387fe694f7; sha256 83cf3d34e94444a27989853b717047cac6e341a36d6a5544501ce757f1f038c4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41874648. Agents can read the archived copy with the MCP tool read_document.